AAP
CATX icon

Arax Advisory Partners’s Perspective Therapeutics CATX Stock Holding History

Arax Advisory Partners’s Portfolio CATX Stock Details CATX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.32K Buy
+387
New +$1.46K ﹤0.01% 4891
2026
Q1 		– Sell
-15
Closed -$41 – 3872
2025
Q4 		$41 Sell
15
-193
-93% -$551 ﹤0.01% 3950
2025
Q3 		$714 Buy
+208
New +$758 ﹤0.01% 3320

Other funds holding CATX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM

Arax Advisory Partners's CATX Position: Q2 2026 in Review

Arax Advisory Partners opened a new position in Perspective Therapeutics (CATX) in Q2 2026: 387 shares worth $1.32K. The stake represents ﹤0.01% of the portfolio and ranks #4891 among its holdings. This is a return to the name: Arax Advisory Partners previously reported a position in CATX as recently as Q4 2025.

Arax Advisory Partners first reported a position in CATX in Q3 2025 and has held it in 3 quarters since. 131 funds tracked by Wall St. Rank hold CATX as of Q2 2026.

  • Arax Advisory Partners held 387 shares of Perspective Therapeutics worth $1.32K as of Q2 2026.
  • Perspective Therapeutics was a new Arax Advisory Partners position in Q2 2026.
  • Perspective Therapeutics made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #4891 holding.
  • Arax Advisory Partners first reported a position in Perspective Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • 131 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.